skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

The noradrenergic symptom cluster: clinical expression and neuropharmacology

Short Report

(1690) Views  (525) Full article downloads

Authors: Blier P, Briley M

Published Date June 2011 Volume 2011:7(Supplement 1) Pages 15 - 20
DOI: http://dx.doi.org/10.2147/NDT.S19613

Pierre Blier1, Mike Briley2
1Institute of Mental Health Research, University of Ottawa, Ottawa, Ontario, Canada; 2NeuroBiz Consulting and Communication, Castres, France

Abstract: Signs and symptoms of depression can be linked to one or more monoaminergic systems, specifically the norepinephrine (NE), the dopamine (DA), and the serotonin (5-HT) systems. In particular, the modulation of energy, vigilance, and arousal can be directly linked to the NE system. There is, however, a great deal of overlap in the modulation of the symptoms of depression between these monoaminergic systems. There are considerable reciprocal interactions between the NE, DA, and the 5-HT systems. When using a selective serotonin reuptake inhibitor (SSRI), for example, 5-HT transmission is enhanced, but at the same time there is a dampening of the activity of NE and DA neurons through inhibitory 5-HT2A and 5-HT2C receptors, respectively. This could explain the residual symptoms of fatigue, lack of energy, and anhedonia, often seen after patients present an overall positive response to a SSRI. Using a dual 5-HT and NE reuptake inhibitor (SNRI), such as milnacipran, would result in an additional increase in NE activity. Futhermore, inhibiting NE reuptake increases DA availability in the frontal cortex since DA is mainly cleared by the NE transporters in several brain regions. A risk inherent in increased NE activity is that of provoking anxiety. This is avoided however by the attenuation of the phasic reactivity of the firing of NE neurons through prolonged administration of SSRI and SNRI.

Keywords: norepinephrine, dopamine, serotonin, residual symptoms, norepinephrine paradox






 

Other articles by Dr Mike Briley

Abnormal laboratory values during the acute and recovery phases in schizophrenic patients: a retrospective study
Antidepressant therapy with milnacipran and venlafaxine
Choking risk among psychiatric inpatients
Editorial Foreword - Milnacipran: recent findings in depression
Improvement of social adaptation in depression with serotonin and norepinephrine reuptake inhibitors
Improvement of the noradrenergic symptom cluster following treatment with milnacipran
Milnacipran and venlafaxine at flexible doses (up to 200 mg/day) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomized, double-blind exploratory study
Milnacipran: a unique antidepressant?
Milnacipran: recent findings in depression
Noradrenergic symptom cluster in depression
Psychiatric diagnoses in patients with burning mouth syndrome and atypical odontalgia referred from psychiatric to dental facilities
Rapid improvement of depressive symptoms in suicide attempters following treatment with milnacipran and tricyclic antidepressants – a case series
Suicidality: risk factors and the effects of antidepressants. The example of parallel reduction of suicidality and other depressive symptoms during treatment with the SNRI, milnacipran
The importance of norepinephrine in depression
The increasing burden of depression
Treatment of patients with comorbid depression and diabetes with metformin and milnacipran


Readers of this article also read:

Depressive and adjustment disorders – some questions about the differential diagnosis: case studies
Pharmacotherapy for treatment-resistant schizophrenia
Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson’s disease: implications for patients
Noradrenergic symptom cluster in depression
The importance of norepinephrine in depression
Is serum brain-derived neurotrophic factor related to craving for or use of alcohol, cocaine, or methamphetamine?
Nano-zinc oxide damages spatial cognition capability via over-enhanced long-term potentiation in hippocamus of Wistar rats
A biological pathway linking inflammation and depression: activation of indoleamine 2,3-dioxygenase
APRESS: apical regulatory super system, serotonin, and dopamine interaction
Neuroimmune endocrine effects of antidepressants